News Category
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial could lead to an additional qualified source of m...
New preclinical research published in the Journal of Virology shows that the mpox virus clade IIb, circulating in the U.S., is up to 100,000 times les...
GeoVax Labs comments on the WHO-declared PHEIC for Bundibugyo Ebola, emphasizing the limitations of strain-specific vaccines and the strategic importa...
GeoVax Labs emphasizes the strategic importance of U.S.-based MVA vaccine manufacturing amid WHO's Ebola emergency and mpox spread, advancing its GEO-...
GeoVax Labs reported a net loss of $5.3 million for Q1 2026 and provided updates on its GEO-MVA mpox/smallpox vaccine candidate, which is advancing to...
